Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
American Airlines Flight Attendant Disappears Amid Layover in Colombia, Authorities Investigating- The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
- Knesset sets special panel to fast-track Karhi’s communications reform
- 4 Famous Attractions at Disneyland
- People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- The Difficulties of Getting a Green Card in the US
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- ONE returns to Red Sea with new service
